Magnus’ SAINT Neuromodulation System receives 510(k) clearance from FDA for treatment of major depressive disorder

Magnus Medical, Inc., a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, today announced it received 510(k) clearance from the U.S. Food & Drug Administration for the SAINTTM Neuromodulation System for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.